Literature DB >> 20713129

Decitabine increases fetal hemoglobin in Papio anubis by increasing γ-globin gene transcription.

Imo Akpan1, Virryan Banzon, Vinzon Ibanez, Kestis Vaitkus, Joseph DeSimone, Donald Lavelle.   

Abstract

OBJECTIVE: The mechanism responsible for increased fetal hemoglobin levels following decitabine treatment remains controversial. These experiments were performed to evaluate the role of transcriptional vs. translational mechanisms in the ability of decitabine to increase fetal hemoglobin levels in vivo.
MATERIALS AND METHODS: Three normal, nonanemic baboons were treated with decitabine subcutaneously (0.5 mg/kg/d) for 10 days. The effect of decitabine on globin chain synthesis and globin messenger RNA levels was measured in pre- and posttreatment bone marrow aspirates by biosynthetic radiolabeling with [(3)H] leucine followed by separation of globin chains by high-performance liquid chromatography, and real-time polymerase chain reaction, respectively. The effect on DNA methylation of the ɛ- and γ-globin gene promoters was determined by bisulfite sequence analysis.
RESULTS: Decitabine treatment of normal, nonanemic baboons induced similar increases in the γ/γ+β chain synthetic ratio and the γ/total β-like globin RNA ratio and also increased expression of ɛ-globin transcripts. Increased expression of ɛ- and γ-globin was associated with decreased DNA methylation of the ɛ- and γ-globin gene promoters.
CONCLUSIONS: Decitabine increases fetal hemoglobin in vivo by transcriptional activation of the γ-globin gene.
Copyright © 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713129      PMCID: PMC4392404          DOI: 10.1016/j.exphem.2010.08.001

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  30 in total

1.  Hemopoietic stress and fetal hemoglobin synthesis: comparative studies in vivo and in vitro.

Authors:  J DeSimone; P Heller; J G Adams
Journal:  Blood       Date:  1979-11       Impact factor: 22.113

2.  Effect of 5-aza-2'-deoxycytidine (Dacogen) on covalent histone modifications of chromatin associated with the epsilon-, gamma-, and beta-globin promoters in Papio anubis.

Authors:  Donald Lavelle; Kestis Vaitkus; Maria Hankewych; Mahipal Singh; Joseph DeSimone
Journal:  Exp Hematol       Date:  2006-03       Impact factor: 3.084

3.  Cellular regulation of hemoglobin switching: evidence for inverse relationship between fetal hemoglobin synthesis and degree of maturity of human erythroid cells.

Authors:  T Papayannopoulou; T Kalmantis; G Stamatoyannopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

4.  Embryonic epsilon and gamma globin genes of a prosimian primate (Galago crassicaudatus). Nucleotide and amino acid sequences, developmental regulation and phylogenetic footprints.

Authors:  D A Tagle; B F Koop; M Goodman; J L Slightom; D L Hess; R T Jones
Journal:  J Mol Biol       Date:  1988-09-20       Impact factor: 5.469

5.  DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.

Authors:  Stela S Palii; Beth O Van Emburgh; Umesh T Sankpal; Kevin D Brown; Keith D Robertson
Journal:  Mol Cell Biol       Date:  2007-11-08       Impact factor: 4.272

6.  Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin.

Authors:  Rodwell Mabaera; Michael R Greene; Christine A Richardson; Sarah J Conine; Courtney D Kozul; Christopher H Lowrey
Journal:  Blood       Date:  2007-10-04       Impact factor: 22.113

7.  5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia.

Authors:  T J Ley; J DeSimone; C T Noguchi; P H Turner; A N Schechter; P Heller; A W Nienhuis
Journal:  Blood       Date:  1983-08       Impact factor: 22.113

8.  5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.

Authors:  J DeSimone; P Heller; L Hall; D Zwiers
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

9.  p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage.

Authors:  A Jiemjit; T E Fandy; H Carraway; K A Bailey; S Baylin; J G Herman; S D Gore
Journal:  Oncogene       Date:  2008-01-28       Impact factor: 9.867

10.  Molecular mechanisms of human hemoglobin switching: selective undermethylation and expression of globin genes in embryonic, fetal, and adult erythroblasts.

Authors:  F Mavilio; A Giampaolo; A Carè; G Migliaccio; M Calandrini; G Russo; G L Pagliardi; G Mastroberardino; M Marinucci; C Peschle
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

View more
  12 in total

1.  Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Authors:  Donald Lavelle; Kestis Vaitkus; Yonghua Ling; Maria A Ruiz; Reda Mahfouz; Kwok Peng Ng; Soledad Negrotto; Nicola Smith; Pramod Terse; Kory J Engelke; Joseph Covey; Kenneth K Chan; Joseph Desimone; Yogen Saunthararajah
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

Review 2.  Potential role of LSD1 inhibitors in the treatment of sickle cell disease: a review of preclinical animal model data.

Authors:  Angela Rivers; Ramasamy Jagadeeswaran; Donald Lavelle
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-08-01       Impact factor: 3.619

3.  δ-Aminolevulinate induces fetal hemoglobin expression by enhancing cellular heme biosynthesis.

Authors:  Li Liu; Xingguo Zhu; Alexander Yu; Christina M Ward; Betty S Pace
Journal:  Exp Biol Med (Maywood)       Date:  2019-08-31

4.  The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis).

Authors:  Angela Rivers; Kestis Vaitkus; Vinzon Ibanez; Maria Armila Ruiz; Ramasamy Jagadeeswaran; Yogen Saunthararajah; Shuaiying Cui; James D Engel; Joseph DeSimone; Donald Lavelle
Journal:  Haematologica       Date:  2016-02-08       Impact factor: 9.941

5.  MBD2 contributes to developmental silencing of the human ε-globin gene.

Authors:  Jeremy W Rupon; Shou Zhen Wang; Merlin Gnanapragasam; Stefanos Labropoulos; Gordon D Ginder
Journal:  Blood Cells Mol Dis       Date:  2011-02-04       Impact factor: 3.039

6.  Extensively self-renewing erythroblasts derived from transgenic β-yac mice is a novel model system for studying globin switching and erythroid maturation.

Authors:  Michael Getman; Samantha J England; Jeffery Malik; Kenneth Peterson; James Palis; Laurie A Steiner
Journal:  Exp Hematol       Date:  2014-04-02       Impact factor: 3.084

Review 7.  Epigenetic regulation of hemoglobin switching in non-human primates.

Authors:  Robert Molokie; Joseph DeSimone; Donald Lavelle
Journal:  Semin Hematol       Date:  2020-12-28       Impact factor: 3.851

8.  Discovery of DS79932728: A Potent, Orally Available G9a/GLP Inhibitor for Treating β-Thalassemia and Sickle Cell Disease.

Authors:  Katsushi Katayama; Ken Ishii; Hideki Terashima; Eisuke Tsuda; Makoto Suzuki; Keiichi Yotsumoto; Kumiko Hiramoto; Isao Yasumatsu; Munefumi Torihata; Takashi Ishiyama; Tsuyoshi Muto; Takahiro Katagiri
Journal:  ACS Med Chem Lett       Date:  2020-12-28       Impact factor: 4.345

9.  In vitro and in vivo induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor.

Authors:  Aidan G Gilmartin; Arthur Groy; Elizabeth R Gore; Charity Atkins; Edward R Long; Monica N Montoute; Zining Wu; Wendy Halsey; Dean E McNulty; Daniela Ennulat; Lourdes Rueda; Melissa Pappalardi; Ryan G Kruger; Michael T McCabe; Ali Raoof; Roger Butlin; Alexandra Stowell; Mark Cockerill; Ian Waddell; Donald Ogilvie; Juan Luengo; Allan Jordan; Andrew B Benowitz
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

Review 10.  5-Aza-4'-thio-2'-deoxycytidine, a New Orally Bioavailable Nontoxic "Best-in-Class": DNA Methyltransferase 1-Depleting Agent in Clinical Development.

Authors:  William B Parker; Jaideep V Thottassery
Journal:  J Pharmacol Exp Ther       Date:  2021-09-09       Impact factor: 4.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.